Expr ss Mail No.: EU733928551US repercher 19, 2002 Date of Dep si

Please type a p DEC 1 9 2002

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449

SUPPLEMENTAL INFORMATION **DISCLOSURE** STATEMENT BY APPLICANT

(use as many sheets as necessary)

09/559,707
04/27/00 RFC
Greenwood DEC 2
1636 TEQUA
Bronwen M. Loeb EUH CENTE
19141-002 CIP

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreig Office	n Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
My	B1	wo	97/40139	Neurotech S.A.	October 30, 1997	
my	B2	wo	97/19694	Amgen, Inc.	June 5, 1997	
TANT	В3	wo	00/10580	Diacrin Inc.	March 2, 2000	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.		
mix	C47	Winton et al. (2000). IOVS 41: S857.		
my	C48	Dunaief et al. (1995). <i>Human Gene Therapy</i> <u>6</u> : 1225-1229.		
TYNT	C49	Greenwood et al. (1996). SV40 71 0165-5728.		
Tint	C50	Dutt et al. (1990). ONCOGENE <u>5</u> 0950-9232.		
TIME	C51	International Search Report for PCT/IB01/00860 mailed October 8, 2002		

^{*} a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, , and relied upon for an earlier filing date under , filed 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	n m for	Date Considered	23 Feb. 2003
-----------------------	---------	--------------------	--------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Part of Paper No. 20

TRA 1633502v2



PATENT TRADEMARK OFFICE